Frontiers in Immunology (Feb 2024)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL

  • Wanying Liu,
  • Jiaying Wu,
  • Xi Ming,
  • Qi Zhang,
  • Delian Zhou,
  • Rubing Zheng,
  • Mi Zhou,
  • Zhen Shang,
  • Liting Chen,
  • Xiaojian Zhu,
  • Yi Xiao

DOI
https://doi.org/10.3389/fimmu.2024.1346001
Journal volume & issue
Vol. 15

Abstract

Read online

BackgroundAnaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare, mature T-cell non-Hodgkin lymphoma. The prognosis of patients with relapsed or refractory ALCL following first-line chemotherapy is extremely poor. NCCN guidelines recommend intensified chemotherapy with or without ASCT consolidation for r/r ALCL, however, this is not an effective treatment for all ALK+ALCL.Case reportHerein, we report a patient with relapsed/refractory ALK+ ALCL who received crizotinib and brentuximab vedotin as bridging therapy, followed by autologous stem cell transplantation and sequential anti-CD30 CAR T cell therapy.ConclusionThe patient achieved complete remission and long-term disease-free survival of months and continues to be followed up. The combination therapy model in this case may provide guidance for the management of relapsed/refractory ALK+ ALCL, and further prospective trials are needed to confirm its effectiveness.

Keywords